Webinar: Different Affiliate-Based Outsourcing Models for Regulatory Affairs
Often questions arise about the Affiliate-Based Outsourcing (ABO) Models for Regulatory Affairs:
1. How can it fit your specific needs?
2. How can it adapt to your organization and setup?
3. What are its possibilities of adjusting to your portfolio?
The purpose of this webinar is to share insights on the Regulatory Affairs Affiliate-Based Outsourcing Model’s flexibility and practical tips on how it can be tailored to your needs. We will share examples of different scenarios on how the ABO model can be customized to optimize costs and efficiently manage your local regulatory operations.
Expanding across Europe?
Make use of our experience. Explore your options in an informal chat with one of our experts.
This webinar focuses on learning:
- What are the options for the Affiliate-Based Outsourcing Model for Regulatory Affairs.
- What are the benefits of different models.
- What are the common challenges and how to overcome them.
- How to select the most beneficial Affiliate-Based Outsourcing Model for you.
Duration: 30 minutes
Speaker: Head of Regulatory Affairs, Olga Bernardova.
Olga Bernardova
Head of Regulatory Affairs
Other content that might interest you:
Effective IMPD Writing. The Quality Part
Webinar: Effective IMPD Writing. The Quality Part Effective IMPD writing, including the quality part is a vital document that contains information about an investigational medicinal product and it is an essential part of the Clinical Trial Application (CTA), which is...
Medical Device Registration in Russia. The Essentials
Webinar: Successful Medical Device Registration in Russia. The Essentials The current national system for Medical Device registration in Russia was created from scratch and entered into force in 2013. Most experts agree that this system is complex and puzzling – some...
Expediting access through Reliance Pathways: MENA region
Reliance models are review pathways used by Regulators to expedite the patient access to essential pharmaceutical products and to overcome resource constraints and priorities. Recently, several National Competent Authorities (NCA) in the Middle East North Africa (MENA) region have implemented the Abridged and Verification reviews. These regulatory procedures allow the approvement of needed innovative and/or life-saving drugs.
